Cooling to Help Injured Lungs (CHILL) Phase 2B Randomized Control Trial of Therapeutic Hypothermia in Patients with ARDS
Abstract
Objectives and Rationale: Acute respiratory distress syndrome (ARDS) is a disease in which the lungs are injured and no longer are able to support the body’s needs for absorbing oxygen and removing carbon dioxide. About 40% of patients with ARDS die. There are no medications available that are effective in patients with ARDS. The objective of the proposed study is to test whether reducing body temperature by 4°F-6°F for 48 hours while giving a paralytic medication to prevent shivering will reduce lung injury in patients with ARDS. The rationale for this study is based on (1) the known effect of cooling to reduce the need for oxygen thereby reducing the work required of the injured lungs and (2) the effect of cooling to inactivate certain molecules that cause the lung injury. Topic Area Addressed: The study addresses the Acute Lung Injury topic area and specifically the development of therapies to reduce severity of lung injury and facilitate transport. Applicability and Impact of the Proposed Research: Treatment with cooling and anti-shivering medications is low tech and utilizes equipment present in military field hospitals, civilian community hospitals, and most Department of Veterans Affairs (VA) hospitals and can be initiated while patients are in the field. Based on estimates of ARDS deaths and the effect of cooling, widespread adoption of the treatment might save ~22,000 patients per year with ARDS in the U.S.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Mar 10, 2021
- Source ID
- W81XWH2010432
Entities
People
- Jeffrey D Hasday
Organizations
- United States Army
- University of Maryland, Baltimore